Briakinumab Biosimilar - HRP Research Grade

In stock

Only %1 left

SKU

ICH5188HRP

Add to Compare

Be the first to review this product

$350.00

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Add to Wish List

Briakinumab Biosimilar - Research Grade: HRP

Unconjugated Product:

Trastuzumab Biosimilar - Research Grade

Conjugate:

Horse Radish Peroxidase (HRP)

Target:

CD30

Clone:

n/a

Isotype:

Human IgG1(E356D/M358L)-Kappa

Other Names:

Receptor tyrosine-protein kinase erbB-2, MLN 19, HER2, HER2/neu

Host:

CHO Cells

Species Reactivity:

Human

Specificity:

Detects human CD30.

Background:

Briakinumab is a humanized Human IgG1(E356D/M358L)-Kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Briakinumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary).

Concentration:

0.5 mg/ml

Formulation:

This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase).

Storage:

This HRP conjugate is stable when stored at 2-8°C. Do not freeze.

Applications:

Flow Cytometry, ELISA

Application Notes:

Each investigator should determine their own optimal working dilution for specific applications.

Use: ichorbio's Briakinumab biosimilar is for research use only (RUO). Isotype Control:

Bulk Human IgG1 Isotype Control (IB1) [ICH2254]